Dominic Cummings may Disagree, but Wealth is Considerably More Heritable than Genes
By Polly Toynbee,
The Guardian
| 10. 14. 2013
Sliding into reverse: that's the unwelcome finding of Alan Milburn's
social mobility and child poverty commission to be published this week. It should send shockwaves through every party, as Milburn challenges the weak incrementalism of both the coalition and Labour in power. This electoral dynamite shows not just the poor, but middling children doing worse than their parents: few good jobs, no homes and heavy debt.
Most people, right or left, would be alarmed at a trajectory of ever-worsening inequality. But few know the facts, wildly underestimating widening wealth gaps, still thinking Britain quite meritocratic. This ends the myth of modern classlessness, exposing shrinking mobility. The ladder up is so high and steep few can climb it – while those at the top exert all their power to stop their children falling down.
All parties praise equality of opportunity, but afraid of overt redistribution they rely on schools to bear the weight of reversing tidal waves of social difference. The report will show how the more equal a society, the less a child's background predicts future success – Labour had...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...